ProCE Banner Activity

DESKTOP III: Improved Survival With Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer

Slideset Download
Conference Coverage
Secondary cytoreductive surgery with complete resection in patients with platinum-sensitive recurrent ovarian cancer and a positive AGO Score leads to substantial improvement in survival outcomes.

Released: June 03, 2020

Expiration: June 02, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono